Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent-Reference-Cited by-同舟云学术

Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent

Published:2022-02-16 Issue:1 Volume:197 Page:63-70
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

On Sandy¹^ORCID,Rath Carolyn G.²,Lan Michelle³,Wu Bobby⁴,Lau Kimberly M.¹,Cheung Edna¹,Alegria William⁵,Young Rebecca²,Tan Marisela²,Kim Carrie⁴,Phun Jennifer⁴,Patel Nimish⁶,Mannis Gabriel⁷,Logan Aaron C.⁸,Kennedy Vanessa⁸,Goodman Aaron⁹,Taplitz Randy A.¹⁰^ORCID,Young Patricia A.¹¹,Wen Raymond⁶,Saunders Ila M.⁶

Affiliation:

1. Department of Pharmacy Stanford Health Care Stanford CA USA

2. Department of Pharmaceutical Services University of California, San Francisco Health San Francisco CA USA

3. Department of Pharmacy University of California, San Diego Health San Francisco CA USA

4. Department of Pharmacy University of California, Los Angeles Health Los Angeles CA USA

5. Department of Quality, Patient Safety and Effectiveness Stanford Health Care Stanford CA USA

6. Skaggs School of Pharmacy & Pharmaceutical Sciences University of California, San Diego La Jolla CA USA

7. Division of Hematology Stanford Cancer Institute, Stanford University Stanford CA USA

8. Division of Hematology and Oncology University of California, San Francisco Health San Francisco CA USA

9. Division of Blood & Marrow Transplant, Department of Medicine University of California, San Diego Health La Jolla CA USA

10. Department of Medicine City of Hope Medical Center Duarte CA USA

11. Division of Hematology/Oncology University of California Los Angeles Medical Center Los Angeles CA USA

Funder

University of California, San Diego

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18051

Reference25 articles.

1. Food and Drug Administration. FDA approves venetoclax in combination for AML in adults. Updated 14 December 2018.https://www.fda.gov/drugs/fda‐approves‐venetoclax‐combination‐aml‐adults.

2. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

3. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

4. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

5. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis;British Journal of Haematology;2024-07-23

2. Treatment challenges and outcomes of older patients with acute myeloid leukemia from India;Annals of Hematology;2024-07-08

3. Treatment challenges and outcomes of older patients with acute myeloid leukemia from India;2024-04-18

4. Venetoclax-Related Neutropenia in Leukemic Patients: A Comprehensive Review of the Underlying Causes, Risk Factors, and Management;Pharmaceuticals;2024-04-10

5. Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies;Open Forum Infectious Diseases;2024-02-06